NASDAQ:JSPRW Jasper Therapeutics (JSPRW) Stock Price, News & Analysis $0.01 0.00 (-2.96%) As of 07/1/2026 03:39 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock About Jasper Therapeutics Stock (NASDAQ:JSPRW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jasper Therapeutics alerts:Sign Up Key Stats Today's Range$0.0130▼$0.013150-Day Range$0.0106▼$0.019352-Week Range$0.01▼$0.15Volume2,031 shsAverage Volume17,490 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Jasper Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability. The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells. JSP191 is designed to enable safer, more precise conditioning prior to stem cell transplantation and in vivo gene therapy by selectively depleting endogenous stem cells while sparing other bone marrow elements. Jasper is also exploring additional cell engineering programs that leverage proprietary platforms to develop next-generation cell therapies, including targeted immunotherapies and regenerative medicine applications. Headquartered in Boston, Massachusetts, Jasper Therapeutics conducts research and development activities in North America and collaborates with academic institutions and industry partners to advance its pipeline. The company’s leadership team brings experience in biologics development, clinical operations and cell therapy manufacturing, positioning Jasper to navigate the regulatory landscape and scale its technologies for broader patient access. Through strategic alliances and a focus on translational science, Jasper aims to move its most promising candidates toward pivotal clinical milestones.AI Generated. May Contain Errors. Read More Receive JSPRW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jasper Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JSPRW Stock News HeadlinesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Keros Therapeutics (KROS), Jasper Therapeutics (JSPR) and Corvus Pharmaceuticals (CRVS)May 17, 2026 | theglobeandmail.comTD Cowen downgrades Jasper Therapeutics (JSPR)May 16, 2026 | msn.comThe energy story near the Grand CanyonA drilling crew near the Grand Canyon confirmed what the IEA calls one of the largest energy resources ever measured - enough to meet global electricity demand 140 times over. They drilled nearly three miles down in just 16 days, a job the Department of Energy projected would take 64. Google signed a 15-year deal. Bill Gates wrote a $100 million check. On July 4th, Washington hands this resource a regulatory edge no other energy source has.July 2 at 1:00 AM | Behind the Markets (Ad)Jasper Therapeutics Inc : JSPRWMay 15, 2026 | 247wallst.comJasper Therapeutics (JSPR) price target decreased by 13.33% to 7.73May 14, 2026 | msn.comEvercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7April 7, 2026 | finance.yahoo.comJasper Therapeutics shares rise 5% on clinical updates despite Q4 lossMarch 31, 2026 | msn.comJasper Therapeutics (JSPR) price target decreased by 30.92% to 8.92March 27, 2026 | msn.comSee More Headlines JSPRW Stock Analysis - Frequently Asked Questions How have JSPRW shares performed this year? Jasper Therapeutics' stock was trading at $0.0401 on January 1st, 2026. Since then, JSPRW stock has decreased by 67.3% and is now trading at $0.0131. How do I buy shares of Jasper Therapeutics? Shares of JSPRW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/02/2026Next Earnings (Estimated)8/07/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 JSPRW's financial health is in the Red zone, according to TradeSmith. JSPRW has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JSPRW CIK1788028 WebN/A Phone650-549-1400FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:JSPRW) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredWhat Happens to Your Assets If You Die Without a Will?Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores ...SmartAsset | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JSPRW Stock Alerts